Gain Therapeutics
Business Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4800 Hampden Ln Ste 200, Bethesda, Maryl...Phone Number
(301) 500-1556Website
www.gaintherapeutics.comRevenue
-Stock Symbol
GANXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Gain Therapeutics
Gain Therapeutics is a biotechnology company founded in 2017 that operates at the intersection of technology and healthcare. The company specializes in drug discovery through its proprietary SEE-Tx target identification platform. This innovative technology identifies and optimizes previously untargeted allosteric binding sites, enabling the development of new treatment options for disorders characterized by protein misfolding. Gain Therapeutics has received recognition and funding from prominent research foundations focused on Parkinson's disease and operates internationally with presence in both North America and Europe. The company is publicly traded and continues to advance its research and development efforts in creating novel therapeutic approaches for challenging medical conditions.Explore more
Gain Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gain Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Gain Therapeutics launches new products
Check if Gain Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Gain Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Gain Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Gain Therapeutics had a recent Job posting/layoffs
Gain Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Gain Therapeutics is spiking on competitors!
Earning: See what the market has to say on Gain Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Gain Therapeutics
Compare insights from companies similar to Gain Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gain Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Gain Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Gain Therapeutics.
Gain Therapeutics Tech Stack
A closer look at the technologies used by Gain Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Project
Gain Therapeutics has reported that at the 150-day follow-up in its GT-02287 clinical program, treatment benefit on the UPDRS scale was maintained at approximately 3 points, with an estimated 6-point gap relative to untreated patients a range considered clinically meaningful.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals
Gain Therapeutics News & Media
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16 in New York City, NY.Gain Therapeutics (GANX) Q2 2026 Summary | Quartr
Summary of Gain Therapeutics (GANX) Q2 2026, combining transcript, slides, and related documents.Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company’s President and CEO, Gene Mack:
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Gain Therapeutics
Sign Up For FreeTo access detailed company insights
Gain Therapeutics is a biotechnology company founded in 2017 that operates at the intersection of technology and healthcare. The company specializes in drug discovery through its proprietary SEE-Tx target identification platform. This innovative technology identifies and optimizes previously untargeted allosteric binding sites, enabling the develop... Read More
